Eli Lilly and Company (SNSE:LLYCL)

Market Cap	783.47T
Revenue (ttm)	57.14T
Net Income (ttm)	17.71T
Shares Out	n/a
EPS (ttm)	19,657.33
PE Ratio	44.25
Forward PE	31.06
Dividend	5,545.25 (0.64%)
Ex-Dividend Date	Aug 15, 2025

Volume	12
Average Volume	15
Open	875,000
Previous Close	875,757
Day's Range	852,500 - 875,000
52-Week Range	608,400 - 940,500
Beta	n/a
RSI	76.89
Earnings Date	Oct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Santiago Stock Exchange
• Ticker Symbol: LLYCL

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD